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Saccharomyces cerevisiaeEss1 is a prolyl isomerase that regulates the structure and function of eukaryotic RNA polymerase II. Ess1 works
by catalyzing the cis/trans conversion of pSer5–Pro6 bonds, and to a lesser extent pSer2–Pro3 bonds, within the
carboxy-terminal domain (CTD) of Rpb1, the largest subunit of RNA pol II. Ess1 is conserved in organisms ranging
from yeast to humans. In budding yeast, Ess1 is essential for growth and is required for efﬁcient transcription
initiation and termination, RNA processing, and suppression of cryptic transcription. In mammals, Ess1 (called
Pin1) functions in a variety of pathways, including transcription, but it is not essential. Recent work has shown
that Ess1 coordinates the binding and release of CTD-binding proteins that function as co-factors in the RNA
pol II complex. In this way, Ess1 plays an integral role inwriting (and reading) the so-called CTD code to promote
production of mature RNA pol II transcripts including non-coding RNAs and mRNAs.
© 2014 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
1.1. Scope of this review
This review will focus on the yeast enzyme Ess1 (Essential 1),
originally discovered in the 1980s, and later shown to play a key role
in RNA polymerase II (pol II) transcription. The human ortholog of
Ess1, called Pin1, has been extensively studied, with thousands of pub-
lications appearing since its isolation in 1996 [1]. Pin1 targets a wide
range of substrates and is proposed to play important roles in cell
growth, development, signal transduction, apoptosis, DNA replication
and repair, stress and immune responses, cancer, inﬂammatory and
neurodegenerative disease, viral latency, and stem cell pluripotency. A
large number of reviews are available that cover these topics [2–9].
With respect to the role of Ess1/Pin1 on regulation of RNA pol II, there
are two excellent although somewhat dated reviews [10,11], and anoth-
er that covers the role of Pin1 on transcription during the cell cycle [12].
The present review will not include studies on transcription factors or
signaling molecules reportedly regulated by Pin1, e.g. NFκB, p53, and
β-catenin [13–16]. Instead, the goal is to introduce the basic structure
and biochemistry of the Ess1 (and Pin1) enzyme and to discuss how
Ess1 controls the RNA pol II machinery.
1.2. Organization of this review
First, a timeline of discoveries will be presented to provide context
and to clarify the relationship between Ess1 family members. Second,
the structures and enzymatic activities of Pin1 and Ess1 will beC-ND license.described. Third, work that linked Ess1 (and Pin1) to transcription by
RNA pol II and current models for how prolyl isomerization regulates
transcription-coupled events will be described. Along the way, the
nature of the carboxy-terminal domain (CTD) of Rpb1, the largest
subunit of RNA pol II will be introduced. Understanding the “CTD-
code” hypothesis is essential to appreciate the role that Ess1 plays in
RNA pol II transcription. Finally, a few transcription-related functions
of Ess1 will be described, and some commentary given on current
limitations to research in the ﬁeld and new directions we expect to
see in the future.
2. Discovery of Ess1 and family members
2.1. Yeast Ess1 was ﬁrst
Ess1 was discovered by serendipity in the early 1980s during the
quest to discover oncogenes in organisms other than their retroviral
hosts — remarkably, even in yeast cells. Working in the laboratory of
Peter Shank, the author carried out low stringency hybridization to
identify a gene that cross-hybridized with the v-sis oncogene, but
which turned out to be unrelated [17]. This genewas named ESS1, on ac-
count of it being essential as shown using gene disruption by homolo-
gous recombination [18]. This was a new method, and at the time it
was a surprise to learn that most genes in yeast were not essential
[19–21]. Using elutriated cells it was shown that ESS1 is expressed con-
stitutively throughout the cell cycle, but only in actively growing yeast.
ESS1 transcript levels diminish as cells enter stationary phase. Although
ESS1 is essential inmost (but not all) strains of Saccharomyces cerevisiae,
the amount of Ess1protein is in excess, as pedigree analysis showed that
cells in which the ESS1 gene is removed grow up to seven generations
Fig. 2.Domain organization of eukaryotic parvulins. TheWWproline-binding domain, the
catalytic domain (PPIase), and the linker region are highlighted. Sc, Saccharomyces
cerevisiae; Dm, Drosophila melanogaster; Hs, Homo sapiens; At, Arabidopsis thaliana. A bac-
terial parvulin (Ec, Escherichia coli) is shown for comparison.
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per cell, whereas only ~400 appear to be sufﬁcient for growth [22]. Early
mutational analysis of ESS1using a conditional tRNA suppressor indicat-
ed a defect late in mitosis or cell wall separation [18] a ﬁnding more
clearly demonstrated using shut-off and temperature-sensitive (ts)
mutant experiments [1,23].
2.2. Its an isomerase!
At the time of its discovery (1984) the sequence of Ess1 did not
reveal similarity to any known protein (unpublished). In that same
year, 1984, Gunter Fischer and colleagues [24] reported the discovery
of an enzymatic activity capable of interconverting the cis and trans
forms of a peptide substrate at the normally restricted prolyl bond
(Fig. 1). These “foldases” as they were known were presumed to help
fold nascent peptides into proteins as they exited the ribosome. Their
activity was shown to be distinct from that of chaperones in that they
targeted a single type of bond, those that precede the amino acid
proline. The enzymes, called peptidyl prolyl cis/trans isomerases (prolyl
isomerases or PPIases) catalyze the reaction in both directions [25–28].
The cis/trans interconversion is non-covalent and does not require ATP,
but instead uses energy derived from conformational changes in the
protein substrates.
It was soon revealed that cyclophilin and FK506-binding protein,
which are the targets of immunosuppressive drugs, are in fact prolyl
isomerases [29–31]. Finally, in 1994 Rahfeld et al. [32], described a
new class of PPIases in Escherichia coli called parvulins (from parvulus,
Latin for very small) that are not sensitive to immunosuppressive
drugs. One year later, Hani et al. [33] recovered ESS1 in a yeast screen
(that will be discussed later) and aptly noted the similarity between
Ess1 (called Ptf1 in their paper) and the newly-described parvulin
class of PPIases. This was a breakthrough, as it revealed a likely bio-
chemical activity for Ess1 and showed that the parvulin class of PPIase
extended to eukaryotic organisms.
2.3. Ess1 is highly conserved
A distinguishing feature of Ess1 is the presence of an amino-terminal
WWdomain.WWdomains are eukaryotic protein-interactionmodules
about 40 residues in length characterized by two signature tryptophan
residues spaced 20–22 aa apart [34–36]. WW domains bind proline-
rich sequences and are not found in prokaryotic (or archaeal) parvulins.
The presence of the distinctive WW domain combined with the
parvulin-type PPIase catalytic domain facilitated the identiﬁcation of
Ess1 orthologs (Fig. 2). Ess1 orthologs have been found in all fungi and
animals that have been examined. The ﬁrst was found in Drosophila
melanogaster encoded by a gene called dodo, so named because it is
located within the ﬂightless region of the X-chromosome that also
contains penguin, ﬂightless and tweety [37]. Remarkably, the dodo gene
driven from a yeast promoter completely rescued (complemented)
yeast cells in which ESS1 was deleted.Fig. 1.Model for phospho-Ser-Pro peptidyl bond isomerization. cis and trans isomers are
shown. Note the 180° difference in the position of the proline's carbonyl group. Oxygens
are shown in red, nitrogens in blue, carbons in gray, the phosphate in orange.The next ortholog discovered was human Pin1, so named because of
its discovery in a two-hybrid assay as a Protein Interactingwith NIMA, a
cell cycle kinase from Aspergillus nidulans [1]. Indeed, human PIN1 fully
rescued yeast cells lacking ESS1 [1]. The notion that Pin1 is amitotic reg-
ulator [38,39] originally derived from the fact that (1) it was isolated by
interaction with NIMA (Never In Mitosis), and (2) the observation that
following shut off of a GAL1–PIN1 construct in ess1Δmutants, cells accu-
mulated in mitosis as large-budded cells and (3) in mammalian cells,
Pin1 antisense constructs showed increased chromosome condensation
consistent with a mitotic defect [1]. It is still not clear in yeast or mam-
malian cells, whether Ess1/Pin1 is a bona ﬁde mitotic regulator, or
whether the cell cycle arrest in yeast (which takes nearly 12 h to
occur) is an indirect consequence of other defects (such as in transcrip-
tion, see below). Pin1 knockouts in mice showed that Pin1 is not essen-
tial although it may help promote the G0 to G1 transition [40].
The ability to complement yeast ess1 mutants has been used as a
litmus test for homology. The simplest method is to complement an
ess1 ts-mutant rather than use a deletion mutant, since most non-
yeast labs prefer not to carry out the requisite tetrad dissection of a dip-
loid ESS1/ess1Δ strain and the subsequent genetic analysis. Orthologs
that complement Ess1 in budding yeast include Xenopus lavis Pin1
(unpublished data), Trypanosoma cruzi Pin1 [41], Schizosaccharomyces
pombe Pin1 [42], Candida albicans Ess1 [43], and Crytococcus neoformans
Ess1 [44]. The yeast complementation assay has also been extremely
useful to monitor the function and enzymatic activity of Ess1-related
enzymes in vivo [23,45,46]. As discussed below, some plant parvulins,
which lack WW domains can complement Ess1 in yeast. Finally, it is
worth noting that in contrast to other PPIases such as the cyclophilins
and FKBPs, which are encoded by multigene families, eukaryotes seem
to contain only one bona ﬁde Ess1 ortholog (containing both a WW and
PPIase domain), making their analysis more straightforward.
2.4. Other eukaryotic parvulins
Eukaryotes also contain a small number of parvulin-class PPIases
that lack a N-terminal WW domain (Fig. 2). Humans contain at least
two Ess1/Pin1-related proteins, hPar14 (parvulin 14 kDa) and hPar17
(parvulin 17 kDa), both encoded by the same gene. hPar14 is expressed
in many tissues, and has PPIase activity, albeit with a 1000-fold lower
catalytic rate and a different target speciﬁcity (Arg-Pro) compared to
Ess1/Pin1 [47,48]. Instead of a WW domain, hPar14 has a basic N-
terminal extension that promotes nuclear localization and DNA-
binding activity [49]. hPar14 is thought to function in pre-ribosomal
RNA processing [50,51] and does not complement yeast ess1 mutants
(unpublished data; [52]. Par17 is a longer isoform of Par14 that is
found only in primates and is targeted to mitochondria [53]. Although
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tous fungi like A. nidulans and Neurospora crassa [54]. The function of
Par14 in those organisms is not clear. There is another PIN1-like gene
in humans, hPIN1L, which is 89% identical to PIN1 over its length, but
it contains a frameshift that would result in a truncated protein [55].
The murine PIN1L is not expressed in any tissue suggesting that PIN1L
is simply a processed pseudogene [56]. Finally, human Gas7b protein,
while not a parvulin (no PPIase activity) contains aWWdomain similar
to that of hPin1, and like hPin1 it binds (and may compete for) phos-
phorylated Tau protein and may be linked to Alzheimer's disease [57].
Plants too, contain parvulin-class PPIases. However, none are strict
orthologs of Ess1/Pin1 (i.e. contain both a WW and PPIase domain).
The ﬁrst discovered was Arabidopsis thaliana Pin1 (PIN1At), which
lacks an N-terminal WW domain yet catalyzes the isomerization of
phospho-Ser-Pro substrates in vitro similar to Ess1/Pin1 [58]. There are
two other parvulins in A. thaliana, AtPIN2 and AtPIN3, but their
sequences are more similar to hPar14 and E. coli Par10, respectively,
and they likely do not share the target speciﬁcity of Ess1/Pin1 [59].
Surprisingly, PIN1At and other plant parvulins, MdPin1 from apple
(Malus domestica) and DlPar13 (Digitalis lanata), despite lacking WW
domains, all rescue yeast ess1 ts-mutants when overexpressed [52,60].
MdPin1 andDlPar13 also show speciﬁcity for phospho-Ser-Pro peptides
[52,60]. In plants, parvulins may function in auxin production [61], and
as shown for A. thaliana, Pin1At isomerizes transcription factors that
regulate the developmental timing of ﬂowering pathways [62].
In summary, all eukaryotes appear to have parvulin-class PPIases,
with fungi and animals containing both Ess1/Pin1-type isomerases
(WW+ PPIase domains) and other parvulins (lacking WW domains).
By contrast, all plant parvulins lackWWdomains. Nonetheless, a subset
of plant parvulins shows Ess1/Pin1-like activities toward peptide sub-
strates. Lastly, an archaeal parvulin has been discovered, and it is most
similar to hPar14 in that it lacks a WW domain and has a substrate
preference distinct from Ess1/Pin1 [63].
3. Structure and speciﬁcity of Ess1/Pin1
3.1. Overall features of Ess1 and Pin1 enzymes
Ess1 and its fungal and metazoan orthologs range from about
163–178 residues in length (Fig. 1). While the sequence identities be-
tween them are relatively modest (typically 38%–44%), the relative po-
sition of the WW and PPIase domains is the same, and several key
residues are essentially invariant. These include the signature trypto-
phan residues of the Ess1 WW domain, W15, W38 (W11, W34 in
Pin1), and several residues that map to the Ess1 catalytic site including
H64, S118, C120, H164 (H59, S111, C113, H157 in Pin1). These andother
highly conserved residues were shown to be functionally important for
growth in vivo [23,46]. For sequence alignments see Arevalo-Rodriguez
et al. [64]. The most comprehensive and illustrative mutational analysis
was carried out by Berhsin et al. [45]whoused a plasmid shufﬂe assay to
introduce a library of 5000 Pin1 mutants (35,000 substitutions) into a
yeast ess1Δmutant background. By screening for functionality (rather
than loss of function) they identiﬁed both tolerated and invariant sub-
stitutions. There weremany surprises, including the fact that several in-
variant residues (e.g. C113, H157 in Pin1) could, in fact, be substituted.
The results are important for understanding catalytic function (see
below). An interesting and somewhat unique feature of these enzymes
is that the two domains, despite being completely dissimilar, bind the
same target sequence— pSer–Pro or pThr–Pro. As discussed inmore de-
tail below, the WW domain binds with ~10-fold higher afﬁnity than
does the PPIase catalytic domain.
3.2. Structures of Pin1 and CaEss1
The ﬁrst structure of a eukaryotic parvulin, Pin1, was solved by the
Noel laboratory [65] (Fig. 3A). The Pin1 structure revealed the N-terminal WW domain and C-terminal catalytic domain are tethered by
a short ﬂexible linker, not all of which was visible in the crystal. The
Pin1 WW domain assumes a compact β-strand structure similar to
WW domains in other proteins. The WW domain in Pin1 (and Ess1) is
a Type IVdomain [66,67]with a strongpreference for substrate peptides
containing phosphorylated serine or threonine preceding proline
(pSer–Pro, pThr–Pro) [68]. The PPIase catalytic site is distal to the hy-
drophobic cleft formed between the two domains (Fig. 3A). The loop
that forms the entrance to the active site contains a series of conserved
basic residues (K63, R68 and R69 in Pin1), explaining the enzyme's pref-
erence for phosphorylated substrates (69). A second Pin1 structure
from the Noel group [69] shows a phosphorylated CTD peptide bound
to the WW domain and positioned in the hydrophobic cleft (Fig. 3B).
A number of direct contacts (not shown) are made between residues
in theWWdomain and Pro3 and Pro5 residues in the peptide substrate
(both in the trans conﬁguration) as well as to phospho-Ser5 (but not to
phospho-Ser2). Notably, while there may be contacts from the long α-
helix (K101) and another residue in the PPIase domain (P153), the ma-
jority of the contacts with substrate are made by the WW domain. This
structure also shows an alternate conformation in which the loop at the
entrance to the active site that contains the three basic residues is ex-
tended away from the body of the protein (Fig. 3B). This suggests that
a mouse-trap type mechanism might occur in the catalytic domain
that could be linked to substrate binding to the WW domain.
In solution, the WW and PPIase domains of Pin1 are mobile relative
to one another, and coalesce upon binding of substrate peptide to the
WW domain [70,71]. Recent studies indicate there may be an interme-
diate state in which transient contacts between theWW and PPIase do-
mains may stimulate substrate binding [72]. These and other studies
suggest a very dynamic Pin1 enzyme that undergoes dramatic confor-
mational changes both with and without added substrate [73]. The
use of bivalent peptides capable of binding both domains has been use-
ful for understanding the ﬂexibility of Pin1 as well as for developing
high-afﬁnity (nM) inhibitors [74].
There is currently no structure available for S. cerevisiae Ess1. How-
ever, the structure of the C. albicans Ess1 is known [75] and provides
an informative comparison to that of human Pin1 (Fig. 3C). The individ-
ual WW and PPIase domains of CaEss1 are virtually superimposable on
those of Pin1, however, there is a striking difference in the linker region
that joins the two domains (shown in red). In CaEss1, this linker is 12
residues longer, is highly structured, contains a four-turn α-helix, and
makes multiple contacts to the PPIase domain (Fig. 3E). Direct contacts
are also observed between the WW domain and the PPIase domain in
CaEss1 that do not occur in Pin1 (Fig. 3E). As a consequence, the WW
is displaced upward, away from the long α-helix in the PPIase domain.
While these differencesmay not have direct implications for the catalyt-
ic mechanism, they are likely to have profound implications for high-
afﬁnity WW-binding to pSer-Pro substrates.
First, the WW and PPIase domains are juxtaposed differently in
CaEss1 effectively eliminating the hydrophobic pocket seen in Pin1
(where substrate peptide binds). Modeling studies indicate the interac-
tion between the CaEss1WWdomain and a phospho-CTD peptide sub-
strate would occur on a different surface of the protein from that seen
for Pin1 (Fig. 3D), even though the individual contacts would likely be
nearly identical (Fig. 3E) [75]. Second, the high degree of ﬂexibilitymea-
sured for Pin1 in solution [70,71] is not likely to exist for CaEss1 due to
themultiple contacts between the linker region and theWWand PPIase
domains (Fig. 4E), which essentially locks them in place. This was
conﬁrmed by NMR solution studies that indicate CaEss1 is highly-
structured throughout its length and tumbles as a unit, even in the ab-
sence of substrate [76]. Third, the path for a substrate to take from the
initial binding site on the WW domain to the PPIase catalytic domain
in each enzyme is likely to be different. This would be especially impor-
tant for long substrates like the CTD of RNA pol II. For a further discus-
sion of the functional implications of the Pin1/Ess1 structures see Li
et al. [75] and Lippens et al. [77].
Fig. 3. Structures of the human Pin1 and Candida albicans Ess1. In ﬁgures (A–E) the PPIase domains are shown in blue, theWWdomains in green, and the linker regions in red. (A) Crystal
structure of human Pin1 at 1.4 Å resolution (PDB ID: 1PIN), with the N and C termini labeled [65]. Not all of the linker is resolved in this structure indicating disorder. (B) Co-crystal struc-
ture of human Pin1 bound to a doubly-phosphorylated (pSer2/pSer5) CTD peptide at 1.8 Å resolution (PDB ID: 1F8A) [69]. All contacts to the peptide are from theWWdomain, none from
the PPIase domain. Note the open conformation of the active-site loop. (C) Crystal structure of C. albicans Ess1 at 1.6 Å resolution (PDB ID: 1YW5) [75]. Note the fully structured linkerwith
prominent α-helix indicated in red, and theWW domain in a different juxtaposition than in Pin1. (D) Structure of the CaEss1 with a CTD peptide modeled on theWWdomain, using the
same interactions seen in the Pin1 structure of (B). (E) Detailed view of CaEss1 showingmultiple contacts between residues in the linker region and theWWdomain to themain body of
the protein (PPIase domain). None of these contacts occur in Pin1. (F) Superposition of theWWdomains of Pin1 (purple) and CaEss1 (green) showing an essentially identical position for
binding of a CTD peptide.
Panels A–F are courtesy of P. Van Roey, and (E, F) are from Li et al. [75], reprinted with permission from the American Chemical Society © 2005.
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Pin1 CaEss1 structures? Although speculative, it is tempting to suggest
that the fungal enzyme, whose structure is less ﬂexible would have a
more restricted substrate speciﬁcity, while the human enzyme, with
its high degree of conformational ﬂexibility between domains would
be able to target a greater variety of substrates. Sequence alignments re-
veal that the fungal enzymes have longer linker sequences than the
metazoan enzymes, and 2° structure predictions show that these longer
linkers could form α-helices, whereas the metazoan enzymes have
short linkers rich in prolines and glycines that would prevent α-helix
formation [75]. While metazoan enzymes have been shown to fully
complement in yeast, the fungal enzymes have never been tested for
complementing ability in animal cells. If the fungal enzymes have
narrower speciﬁcities, then they would not be expected to fully rescue
in animals.3.3. Substrate speciﬁcity and catalytic mechanism
Prolyl isomerases accelerate the cis–trans isomerization of the pep-
tide bond within peptide substrates by a factor of 103–106 [27,78,79].
For example, the rate of isomerization of CTD peptides is increased by
S. cerevisiae Ess1 by 103 from a spontaneous rate of ~1 turnover/min
to a catalyzed rate of 47/;17/s [22]. The rate of spontaneous and cata-
lyzed isomerization within intact proteins may be lower. An in vivo ex-
pression titration system was used to measure the total number of Ess1
molecules per cell required for yeast viability, and by extension, the
number of turnovers required for viability under different growth
conditions [22]. In richmedium, ~6000 Ess1-catalyzed turnovers/s are re-
quired per cell for robust growth. However, as few as 20–300 turnovers/s
will supportminimal growth. Under stress conditions (e.g. hygromycin B,caffeine), much higher levels of Ess1 are required for viability,
since ~6000 turnovers/s was not sufﬁcient for growth [22].3.3.1. Measuring binding and isomerization by Ess1/Pin1-type PPIases
Despite their small size (~19.5 kDa) the Ess1/Pin1-type parvulins are a
challenge to study biochemically. This derives from the fact that (1) both
the PPIase and WW domains bind the same phospho-Ser/Thr-Pro sub-
strates, (2) in isolation, the catalytic domain has a very low afﬁnity for
substrates, (3) the reaction is reversible — the products are not easily
“captured” and are in turn used as substrates, and (4) it is difﬁcult tomea-
sure isomerization using physiological targets (intact proteins). It is a tes-
tament to the ingenuity of researchers in the ﬁeld, including Kurt
Wuthrich, Harold Scheraga, Franz Schmid, Gunter Fischer and others
[24,80–83], that a number of useful methods have been developed to
study isomerization of peptide and protein substrates by these enzymes,
reviewed in [27].
Binding to proline-rich peptides or proteins can bemeasured using a
variety of general techniques including ﬁlter immunoblots [84], two-
hybrid analysis [85], GST-pulldown [86], ﬂuorescence anisotropy [68],
circular dichroism (CD) [87], NMR [88], and most recently by biolayer
interferometry (BLI) [89]. Only apparent dissociation constants (Kapp),
however, can be determined for intact Ess1/Pin1 proteins because of
the dual-bindingmode. Expression of individualWWor PPIase domains
or mutants thereof is necessary to resolve individual binding constants.
For full-length Pin1, Kapp was measured by ﬂuorescence anisotropy to
be 10, 30 or 60 μMfor CTDpeptide doubly phosphorylated or phosphor-
ylated on Ser5 or Ser2, respectively [69]. The bulk of the binding afﬁnity
was contributed by the WW domain. For example, on the doubly-
phosphorylated CTD peptide, the Kd for the isolated WW domain was
34 μM, while the Kd for the PPIase domain was 390 μM.
Table 1
Binding afﬁnities and turnover rates of eukaryotic parvulins.
Protein Substrate Kda (μM) Method Refs. Turnover Method Refs.
Sc Ess1 Unphosp. CTD N3000
N300
FA; BLI [22,89] 0 s−1 NMR [22]
pSer2 CTD 241 ± 23 FA [22] 2.8 s−1 NMR [22]
pSer5 CTD 61 ± 4.9
2.6 ± 0.7
FA; BLI [22,89] 17.7 s−1 NMR [22]
Sc Ess1 WW Unphosp. CTD n.b. CD [87] n.a. n.a. n.a.
pSer2 CTDb 67 ± 11 CD [87] n.a. n.a. n.a.
pSer5 CTDb 79 ± 13 CD [87] n.a. n.a. n.a.
pSer2,5 CTDb 21 ± 3 CD [87] n.a. n.a. n.a.
Sc Ess1 Ac-ApSPY-pNA n.d. n.a. n.a. 17,200 mM−1 s−1 Protease-coupled [114]
Hs Pin1 Ac-ApSPY-pNA n.d. n.a. n.a. 3370 mM−1 s−1 Protease-coupled [94]
Sc Ess1 Ac-AApSPR-NH-Np n.d. n.a. n.a. 12,000 mM−1 s−1 Protease-coupled [90]
Hs Pin1 Ac-AApSPR-NH-Np n.d. n.a. n.a. 9500 mM−1 s−1 Protease-coupled [90]
Hs Pin1 pSer2 CTD 61 ± 6.3 FA [69] n.d. n.a. n.a.
pSer5 CTD 30 ± 0.39 FA [69] n.d. n.a. n.a.
pSer2,5 CTD 10 ± 0.8 FA [69] n.d. n.a. n.a.
Hs Pin1 WW pSer2 CTD 110 ± 23 FA [69] n.a. n.a. n.a.
pSer5 CTD 34 ± 5.9 FA [69] n.a. n.a. n.a.
pSer2,5 CTD 34 ± 6.2 FA [69] n.a. n.a. n.a.
Hs Pin1 PPIase pSer2 CTD n.b. FA [69] n.d. n.a. n.a.
pSer5 CTD N500 FA [69] n.d. n.a. n.a.
pSer2,5 CTD 390 ± 6.82 FA [69] n.d. n.a. n.a.
Ca Ess1 Suc-AEPF-pNA n.d. n.a. n.a. 19 s−1 Protease-coupled [75]
Hs Par14 Suc-ARPF-pNA n.d. n.a. n.a. 4.0 mM−1 s−1 Protease-coupled [47]
At Pin1 Ac-WFYpSPRLR-NH n.d. n.a. n.a. 1 s−1 NMR [58]
n.b. = no binding detected; n.a. = not applicable; n.d. = not determined; FA = ﬂuorescence anisotropy; BLI = biolayer interferometry; NMR = nuclear magnetic resonance
chemical shift; CD = circular dichroism thermal denaturation; caution is advised when comparing values obtained by different groups using different methods; the concentrations of
protein and substrates used as well as the temperatures and buffer conditions may differ. Turnover rates are given as turnovers per second (s−1), or as Kcat/Km (mM−1 s−1).
a For full-length proteins apparent Kd.
b Circularly permutated relative to other studies.
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be 60 μM and 240 μM for CTD peptides phosphorylated on Ser5 and
Ser2, respectively [22]. Using a different method (BLI), the Kapp of intact
Ess1 for a Ser5 phosphorylated peptide was estimated at 2.1–2.6 μM
[89]. Binding afﬁnities of the isolated WW-domain of Ess1 were mea-
sured using CD to be ~70 μM for pSer2 peptides, 80–100 μM for pSer5
peptides and ~20 μM for doubly-phosphorylated peptides [87]. For both
Pin1 and Ess1, binding to unphosphorylated Ser/Thr-Pro peptides is es-
sentially undetectable. Despite the quantitatively different results report-
ed by different laboratories using differentmethods and substrates, a few
common themes emerge. First, Ser/Thr-Pro substratesmust be phosphor-
ylated to bind. Second, longer doubly-phosphorylated substrates tend to
bind better. And third, even with the best substrates, the binding afﬁnity
is relatively weak, typically in the micromolar range. A summary is pro-
vided in Table 1.
Accurate measurement of isomerization rates in vitro is possible, but
has its limitations because the simplest assays use unnatural substrates,
whereas natural substrates are difﬁcult or impossible to assay. Methods
include the standard protease-coupled assay that uses non-physiological
substrates [24], a set of ﬂuorescence-based assays that rely on solvent or
pH jumps but offer more ﬂexibility in allowable peptide sequences [90],
and dynamic NMR methods (chemical exchange) that can monitor indi-
vidual isomerizations within natural peptide or protein substrates
[91,92]. For a review that describes these methods with additional refer-
ences see [27]. As expected, measuring isomerization in intact proteins
is the most difﬁcult but has been done with well-behaved proteins such
as RNaseA and bovine pancreatic trypsin inhibitor (BPTI) [93]. Unfortu-
nately, at this time there is no reliable way to monitor isomerization
in vivo.
For Pin1, isomerization rates have been measured by multiple
methods on a wide variety of peptide substrates, with Tyr-pSer-Pro-
Arg motif-containing peptides showing the highest rates [90,94]. Ess1-
catalyzed isomerization of CTD peptides (AS[YS2PTS5PS]YS) was mea-
sured using chemical exchange and revealed a 6-fold higher rate on a
peptide phosphorylated on Ser5 (17.7 turnovers/s) than on Ser2
(2.8 turnovers/s) [22] (Table 1). This ﬁnding correlated with geneticsuppression experiments in yeast that suggested that Ser5–Pro6 in the
CTD was the more relevant in vivo target [95]. Based on these and
other ﬁndings discussed below (Section 5.3), it appears that Ess1 may
bind doubly-phosphorylated CTD substrates best, but prefers to catalyze
isomerization of the pSer5–Pro6 bond within the CTD repeats.
3.3.2. A speciﬁcity problem
Similar to the situation for many DNA-binding proteins [96,97], the
Ess1/Pin1-type isomerases appear to have a “speciﬁcity problem”. Ser-
Pro and Thr-Pro sites are ubiquitous in proteins and are phosphorylated
by cyclin-dependent and mitogen-activated kinases, CDKs and MAPKs
[98–100]. How do Ess1/Pin1-type isomerases recognize bona ﬁde sub-
strates given the widespread occurrence of pSer-Pro and pThr-Pro mo-
tifs in the proteome? While there are some minor preferences for
ﬂanking residues [86], the totality of studies show promiscuous binding
to pSer/Thr-Pro-containing targets of in vitro. As a consequence, either
these PPIases do in fact target multitudes of proteins in the cell, or
their interactions are restricted in some unknown way. Several poten-
tial mechanisms come to mind. First, the pSer/Thr-Pro motifs within
mature proteins might be buried within their three-dimensional archi-
tecture and therefore might not be accessible. Second, these sites might
be masked by the binding of competing proteins. Third, these PPIases
might require cooperative or combinatorial bindingwith other proteins
to help target them to physiological substrates. There is currently little
evidence to distinguish among these possibilities. We suspect that in
yeast, Ess1 may simply require that substrates have multiple repeats
(or proximally-located copies within their 3D-structures) of the pSer/
Thr-Pro motif, as found in the CTD of RNA pol II discussed in
Section 5.2. While the issue of speciﬁcity is largely ignored in the litera-
ture, it is likely to be important particularly in higher organisms where
there are so many substrates of Pin1 reported (see also Lippens for dis-
cussion) [77].
3.3.3. Catalytic mechanism and inhibitors
The mechanism of the prolyl isomerization by Pin1 was originally
proposed to involve a covalent intermediate formed by nucleophilic
Fig. 4.Genetic interactions between ESS1 and RNA polymerase II are conserved from yeast
to metazoans. (A) Diploid yeast cells of the indicated genotype were grown at permissive
temperature (30 °C) on rich medium (YEPD). Reducing the dosage of the largest subunit
of RNA pol II (RBP1/rpb1Δ) combined with an ess1H164R ts-mutant is synthetic lethal.
(B) Reduced maternal dosage of the fruit ﬂy Ess1 (Dodo) enhances the larval defects in
the reduced activity RNA polymerase II mutant, wimp. wimp is a dominant negative
maternal-effect mutant in Rpb2 [121]. Cuticle preparations of ﬁrst instar larvae of the
indicated genotype are shown with the anterior to the left and dorsal up. Thoracic and
abdominal defects occur in the doublemutant (arrows). Bristle patterns reveal segmental
defects including fusions and a general disorganization of anterior–posterior axial pattern-
ing. Viability is also reduced (N. Singh and S.D. Hanes, unpublished results).
Data in (A) are fromWu et al. [23], and are reprinted with permission from the Nature
Publishing Company.
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tionedmutagenesis study suggested otherwise, since a C113D substitu-
tion was functional in vivo and retained about 30% catalytic activity
in vitro [45]. Indeed, C. albicans Ess1, which has activity comparable to
that of Pin1 [75], normally carries an aspartate at this position. Detailed
studies with inhibitors and substrate analogs have revealed more likely
catalytic mechanisms for Pin1 [73,101–104]. Evidence supporting a
twisted-amide mechanism was described by Etzkorn and colleagues
[101]. They suggested that the phosphate group of the pSer-Pro motif
and the proline carbonyl are locked in place by hydrogen bonds from
K63, R68 and R69, and Q131 of Pin1, respectively. The rotation involves
a “jump-rope” type motion resulting in rotation of the serine carbonyl
group via a transition state that bears an intramolecular hydrogen
bond within the substrate from the Pro-X amide NH group to the pro-
line nitrogen. This bond is proposed to stabilize the transition-state
intermediate.
The basis for the twisted-amide bondmodel derives from older stud-
ies with cyclophilins and FKBPs [105,106], as well as the structures ofPin1-inhibitor complexes from the Noel laboratory [102]. In support of
this model, substrates with a proline at the +1 position (pSer/pThr-
Pro-Pro), which lack the amino hydrogen required for the hydrogen
bond that stabilizes the twisted state (β-turn), were found to bind the
PPIase domain lesswell than other substrates, although this could instead
be due to loss of a potential hydrogen bond to the carbonyl oxygen of the
pSer/pThr [86].
Chemical inhibitors have been helpful in understanding not only the
catalytic mechanism but also the basis for binding and selectivity of
both the PPIase and WW domains. These studies are driven by the po-
tential clinical signiﬁcance of Pin1 in a number of human diseases. The
ﬁrst reported inhibitor, juglone [107], has beenwidely used in biological
studies. This is unfortunate, as it is a relatively non-speciﬁc inhibitor.
While it inhibits the parvulin-class Ess1/Pin1 isomerases but not
cyclophilins or FKBPs, it works by covalent modiﬁcation of Cys residues.
Since active-site Cys residues are common inmany enzymes such as py-
ruvate decarboxylase, glutathione-S-transferase and RNA polymerase II,
results obtained from the use of juglone are of questionable value [90].
Other potent and speciﬁc inhibitors have been identiﬁed. These in-
clude peptidomimetics such as D-isomer and cyclic peptides, and
conformationally-locked isosteres [84,90,102,108–111]. Selective
WW-domain inhibitors have also been identiﬁed [112]. Studies using
cis-locked or trans-locked inhibitors revealed, among other things,
that the PPIase domain prefers the cis-isomer, while the WW domain
is rather non-selective, and that there is intramolecular signaling be-
tween the WW and PPIase domains [113]. On substrates with multiple
pSer/pThr-Pro bonds such as the CTD, these ﬁndings imply that
targetingwould occur via theWWdomain if the substrate bonds are ini-
tially in trans, and that binding to the WW domain could potentially
alter catalytic activity of the PPIase domain. Flanking sequences may
also inﬂuence WW vs. PPIase preferences, for example, as mentioned,
proline at the +1 position (pSer/pThr-Pro-Pro) favors WW-domain
binding over PPIase binding [86].
In summary, although certain aspects of the Ess1/Pin1 family of en-
zymes are reasonably well-understood from a structural and biochemi-
cal standpoint, further studies will be needed to fully understand the
catalytic mechanism and to identify potential binding differences with
distinct substrates, as well as to determine how the sequences of
amino acid residues ﬂanking the X-Pro target affect catalytic rates. An-
other future goal is to understand how longer, multi-site substrates
bind and to determine the path taken from binding site on theWWdo-
main to the active site of the PPIase domain. Finally, understanding the
structural and functional differences between metazoan and fungal en-
zymesmay provide clues to their evolutionary divergence, crosstalk be-
tween the two domains, and highlight differences in their respective
substrate spectrum.4. Ess1 plays a role in RNA polymerase II transcription
4.1. Early studies linking Ess1 to transcription
The ﬁrst hint that Ess1 was involved in transcription came in 1995
[33]. At the time, this link to transcription was overlooked probably be-
cause the relevant experiments, a genetic screen for rescue of a 3′-end
processing defect that identiﬁed ESS1 (called PTF1 in that study), were
simply cited as unpublished results. Instead, the paper emphasized the
similarity of Ess1 (Ptf1) to bacterial parvulin-class PPIases, which of
course was also very important. A follow-up study, published in early
1999 described the screen and showed that ess1mutants read through
poly(A) termination sites embedded in reporter constructs [114]. This
prescient study also demonstrated Ess1/Ptf1 PPIase activity for the
ﬁrst time. Biochemical studies showed that Pin1 and Ess1 interacted
in vitro with the phosphorylated form of RNA polymerase II or
phospho-CTD peptides, respectively [115,116], although these studies
did not provide evidence that the interaction was functional.
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to carry out an unbiased high-copy suppressor screen to look for clues
about Ess1 function [23]. The expectation, based on the supposedmitotic
function of Ess1 and Pin1 was that cell cycle regulators would be identi-
ﬁed. Instead, all but one suppressor was transcription-related and re-
maining suppressor was cyclophilin A, another PPIase. Among the
suppressors, YKL005C, now known as BYE1 (bypass of Ess1) encodes a
likely elongation factor that interacts directly with RNA polymerase II
[117,118]. Another, FCP1, encodes a CTD-phosphatase [119] and a third,
SAP30, encodes a component of a histone deacetylase complex [120].
In the same study, Ess1 was shown to interact biochemically and
in vivo (using two hybrid and genetics) with RNA polymerase II, and
ess1mutations showed defects in transcription of individual genes [23].
A powerful genetic experiment that functionally linked Ess1 to RNA po-
lymerase II function in yeast cells is reproduced in Fig. 4A. It shows the
synthetic-lethal effect of reducing both Ess1 and the largest subunit of
RNApol II (Rpb1),which bears the pSer-Pro containing CTD. Remarkably,
a similar result is seen in whole animals, where a dodomutation com-
binedwith a reduced activity RNA pol II allele (calledwimp) [121] results
in cuticular defects in embryos, whereas mutation of either one alone
does not (unpublished data; Fig. 4B). Ess1 mutants were also shown to
be synthetic lethal with CTD-truncation alleles and interact genetically
with SRB2 (synthetic lethal) a gene originally isolated as a suppressor
of CTD truncations and part of the mediator complex [23,95].
Based on these studies, a model for Ess1 function was proposed in
which Ess1 binds the phosphorylated formof the RNApol II CTD, and in-
duces conformational changes that regulate the binding of protein co-
factors required for the transcription cycle [23]. A number of genetic
studies supported the idea that Ess1 function is important during mul-
tiple stages of the transcription cycle including initiation, elongation
and termination [85,95,118,122]. In particular, these and other studies
suggested that Ess1 promotes the activity of CTD phosphatases and op-
poses the action of CTD kinases [123], reviewed in [64]. The model was
expanded to include Ess1 and isomerization of the CTD as an integral
part of the CTD code [124] (described in Section 5).
Following the initial studies in yeast, work from theManley laborato-
ry linked human Pin1 to transcription. In these studies, Xu et al. [125]
used in vitro assays and in vivo approaches with the inhibitor juglone,
as well as pin1−/− knockout mouse embryo ﬁbroblasts [40] and Pin1
overexpressing HeLa cells. They showed that Pin1 inhibits the CTD-
phosphatase activity of Fcp1, which was also shown by Palancade et al.
[126] who found that inhibition was likely due to steric hindrance (at
least in vitro), and not necessarily requiring PPIase activity. In addition,
Pin1 stimulated CTD phosphorylation by Cdc2/CyclinB and promoted
hyperphosphorylation of RNA pol II [125]. Finally, they showed that
Pin1 inhibited in vitro transcription (and splicing) and in later work pro-
posed that Pin1 acts to shut down transcription during themitotic phase
of the cell cycle [127].While these studies conﬁrmed a conserved role for
Pin1 in mammalian transcription via regulation of RNA pol II, the effects
differed in “direction”with those observed in yeast. As described below,
in yeast, Ess1 seems to promote de-phosphorylation of the CTD, while in
mammalian cells, Pin1 seemed to promote phosphorylation of the CTD.
It is possible that the difference is due to distinct cell cyclemechanics, for
example the lack of nuclear envelope breakdown or transcription shut-
down duringmitosis in yeast. To date, however, there is no adequate ex-
perimental explanation for the observed differences. Perhaps careful
measurements of cell cycle-dependent CTDmodiﬁcation (along speciﬁc
loci and genome-wide) might help resolve the differences.
4.2. Loss of Ess1 has effects on transcription genome-wide
4.2.1. Use of temperature-sensitive (ts) alleles
Ess1 mutants show a variety of transcription-related defects. Since
ESS1 is essential, almost all functional studies have been doneusing con-
ditional (ts)mutants. Themost commonly used allele is ess1H164R, which
has a mutation in the catalytic site (H164R) that reduces PPIase activity~10,000 fold [22] and renders the cells temperature sensitive [23]. Cells
bearing this allele grow normally at 23–30 °C, but fail to grow at 37 °C.
The defect is likely due to the catalytic deﬁciency since the Ess1(H164R)
protein binds CTD peptides about as well as the wild-type protein [22].
Other ts-alleles commonly used include A144T [23], which also has a
stop codon substitution leading to a longer protein (33 additional resi-
dues) (unpublished data), and G127D, and another PPIase domain mu-
tation independently isolated by two groups [23,114]. Both A144T and
G127D mutant proteins are less stable than the H164R mutant protein
at 37 °C [23].
To better understand the yeast Ess1 literature, two important points
need to be kept in mind. First, defects in transcription in the ts-mutants
are apparent even at permissive temperature, especially for the
ess1H164R allele [128,129]. This is probably why genetic interactions
can be observed at semi-permissive (34 °C) and permissive tempera-
tures (25°, 30 °C) [85,95,118,122]. The ability to detect defects at these
temperatures allows the experimenter to avoid potential complicating
factors associated with prolonged incubation at (37 °C) including heat
shock response, and transcriptional reprogramming and the onset of
cell death. The second point is related, but more subtle. The fact that
ess1H164R mutant, whose catalytic activity is dramatically reduced, is
even viable at permissive temperature indicates that very little Ess1 ac-
tivity is required for growth. Or put another way, normally (in rich
media) Ess1 activity is present in great excess. This was demonstrated
by Gemmill et al. [22]. In addition, we and others have found that the
catalytic activity of Ess1(H164R) protein does not appear to be
thermo-labile [22], and the protein is not degraded in cells shifted to
37 °C (although its level is somewhat reduced) [22,23]. These ﬁndings
indicate that the temperature-sensitivity is likely due to a heightened
requirement for Ess1 activity at the elevated temperature (i.e. a stress
condition), and not strictly due to diminished Ess1 activity at the elevat-
ed temperature. This conclusion is consistent with ﬁndings that high
levels of Ess1 are required for viability under other stress conditions,
such as addition of hygromycin B or caffeine [22]. Thus, genetic and bio-
chemical effects observed at restrictive temperaturesmust take into ac-
count the increased requirement for Ess1 activity and the reason for the
temperature-sensitivity.
4.2.2. Ess1 is important for efﬁcient termination of mRNAs and small non-
coding RNAs
Hani et al. [114] observed a decrease in total poly(A)-plus RNA follow-
ing a shift of a ts-mutant (ess1G127D) to restrictive temperature. They also
observed readthrough of anACT1promoter-lacZ construct intowhichwas
inserted an ADH1 terminator-poly(A) sequence, suggesting a defect in 3′-
end processing. This defect was conﬁrmed using a different allele
(ess1H164R) and a different terminator (ADH2) [118,122], and readthrough
was measured to be nearly 20% in ess1H164R mutants relative to control
cells [118]. These were early indications that Ess1 might help coordinate
recruitment of the termination and/or 3′-end mRNA processing machin-
ery to the RNA pol II complex. Details are discussed in Section 5.
Efforts to gauge the global importance of Ess1 for mRNA 3′-end for-
mation used genome-wide approaches that included high-density tiling
arrays. Surprisingly, these efforts did not uncover broad readthrough of
mRNAs in ess1H164R mutants [129]. While some examples of mRNAs
readthrough transcription were observed, the majority of effects were
on small non-coding RNAs (discussed below). It was not until the use
of genetic backgrounds in which mRNA decay pathways were
inactivated that transcription readthrough in ess1mutantswas revealed
to be wide-spread [128]. About half of the fourteen genes examined in
ess1H164R cells that also carried a deletion of the UPF1 gene showed sig-
niﬁcant readthrough transcription.UPF1 (also knownasNAM7) encodes
an RNA helicase required for nonsense-mediated decay (NMD) [130].
Indeed ess1H164R upf1Δ double mutants showed synthetic growth de-
fects. This was interpreted [128] to indicate that in double mutant
cells the accumulation of readthrough transcripts might contribute to
their demise, whereas in ess1H164R UPF1+ cells, where the NMD decay
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[131,132].
Mutations in other RNA surveillance/decay pathway genes, XRN1
and RRP6were also synthetic lethal with ess1H164R. XRN1 encodes a cy-
toplasmic 5′→ 3′ exonuclease located in P-bodies and RRP6 encodes a
3′→ 5′ exonuclease that is part of the nuclear exosome complex. Both
function in RNA processing and in destruction of aberrant RNAs
[133,134]. While no genome-wide analysis of ess1H164R mutants has
been done in mRNA decay-deﬁcient backgrounds, based on experi-
ments done thus far it is likely that 47/;50% of all mRNA genes will re-
quire Ess1 for efﬁcient transcription termination/3′-end processing
[128].
Using an in vitro 3′ mRNA processing assay, Krishnamurthy et al.
[122] showed that Ess1 was dispensable for efﬁcient cleavage and
polyadenylation. If this is also true in vivo, it would suggest that the
readthrough defects in ess1 mutants are due to termination defects
and not to the requisite 3′ cleavage and poly(A) addition events that
occur prior to actual termination and RNA pol II disengagement from
the DNA template. However, lack of activity in vitromust be interpreted
with caution. In vitro transcription also does not require Ess1 [135]. It is
possible for example, that in vitro, the processing factors are present in
such excess that Ess1's effects would not be required.
Ess1 is also critically important for the termination and 3′-end pro-
cessing of small non-coding RNAs. This was discovered somewhat indi-
rectly. Using standard ORF microarrays, it was shown that the
expression of ~10% of all protein-coding genes was affected in
ess1H164R mutants. What was striking, however, was that the small set
of genes whose expression increased was nearly identical to those ob-
served in microarray experiments with ssu72 mutants [136]. As will
be described in more detail below, SSU72 encodes a pSer5-speciﬁc
CTD phosphatase. Further analysis revealed that the reason these
protein-coding genes showed increased microarray signals in ess1H164R
mutant cells was because of transcriptional readthrough from adjacent
small nucleolar RNA (snoRNA) genes, the same results found in the
ssu72 study. snoRNA genes are transcribed by RNA pol II but their tran-
scripts are not polyadenylated or exported and serve as guides in rRNA
processing events [137]. In ess1H164Rmutants, nearly all independently-
transcribed snoRNA genes (~30) show transcriptional readthrough
[129]. In some cases readthrough transcription led to decreases in the
expression of downstream genes. No effects were observed for small
nuclear RNAs, e.g. U1–U5, which are part of the nuclear spliceosome.
Preliminary work in human cells indicates that Pin1 siRNA knockdown
cells show similar readthrough of at least some independently-
transcribed snoRNAs (unpublished data).
Ess1 is also required to keep cryptic unstable transcripts (CUTs)
[138] under control [129]. Tiling array analysis revealed that a large
numbers of CUTs are stabilized in ess1H164R mutant cells. This includes
hundreds of CUTs already been identiﬁed in other mutant backgrounds
(e.g. rrp6) and a similar number that appear to be unique to ess1 mu-
tants [129]. The CUTs were in 5′, 3′ and intergenic regions of protein-
coding genes in both sense and antisense directions. Their ubiquity
throughout the genome suggests that there is a global defect in tran-
scription repression in the ess1H164R mutant, perhaps chromatin-
mediated. Many CUTs seemed to be stabilized due to failure to termi-
nate at their normal sites, which is required to initiate their degradation
[139,140]. Instead the elongated transcripts extended into neighboring
genes or promoters, oriented in the same or opposite direction, often
resulting in their increased or decreased expression [141–144]. Analo-
gous results were observed for ess1 mutants in C. albicans using high-
throughput RNA-seq analysis [145]. In summary, ess1 mutants show
genomic chaos due to faulty mRNA and small non-coding RNA
termination/3′-end formation and to high levels of cryptic transcription.
4.2.3. Ess1 affects initiation and elongation
In several studies, ess1 mutants failed to activate reporter
genes under inducing conditions [23,122,146]. Since these reporters(LexA-lacZ, PHO5-lacZ, GAL10-lacZ, INO1-lacZ) are driven by different ac-
tivator proteins (LexA-GAL4, Pho4, Gal4, Spt23), the loss of expression
was not likely due to an activator-speciﬁc defect, but more likely to a
general defect in initiation. As expected if Ess1 has a role in initiation,
chromatin immunoprecipitation (ChIP) data showed that Ess1 is
present at the 5′ end of several highly-expressed genes [23,122].
The idea that Ess1 plays a role in initiation is supported by genetic in-
teractions observed betweenmutations in ESS1 and SUA7 (TFIIB), KIN28
(TFIIH kinase), and SRB10 (a kinase component of the mediator com-
plex), all of which have roles in initiation or preinitiation. Overexpres-
sion of SUA7 suppresses ess1 growth defects, suggesting a positive role
for Ess1 in initiation. That is, loss of Ess1 function is overcome by high
levels of the initiation factor TFIIB [122]. KIN28 and ESS1 have an antag-
onistic relationship [95] suggesting that Ess1 may reverse the action of
the Kin28 kinase, which generates Ser5-phosphorylated CTD at the
time of promoter escape and promotes 5′ capping [147]. Finally and
most remarkably, an srb10Δ mutation fully restores viability to an
ess1Δmutant [95]. The Srb10 (Cdk8) kinase, part of the mediator com-
plex, phosphorylates the CTD and was thought to have an inhibitory
role prior to pre-initiation complex formation (PIC) [148]. Ess1 might
promote dephosphorylation of the CTD after its phosphorylation by
Srb10. If true, then the genetic results can be explained as follows:
When Srb10's negative effect on PIC is removed, Ess1 is no longer need-
ed because initiation occurs unperturbed. Themechanism is likelymore
complex, as Srb10/Cdk8 also targets other proteins in the initiation
complex and has been shown to promote initiation and elongation
[149,150].
Several lines of evidence suggest that Ess1 may also control elonga-
tion, probably by slowing it. First, there are strong genetic interactions
between ESS1 and CTK1 (elongation-related CTD kinase), DST1 (elonga-
tion factor TFIIS), and SPT4/SPT5 (elongation factor complex, DSIF)
[23,95]. For example, ESS1 and DST1 (which promotes elongation)
oppose one another genetically. Second, ess1 mutants show increased
readthrough of an ARTAR-artiﬁcial pause/arrest site reporter. Third,
ess1 mutants are resistant to the elongation inhibitor 6-azauracil (6-
AU) suggesting Ess1 normally slows elongation, and in ess1 mutants,
elongation rates would increase [23]. This result, by itself would not
be signiﬁcant since changes in 6-AU sensitivity can result from a num-
bermechanisms unrelated to elongation rates. For example, 6-AU resis-
tance could bedue to increased transcription of IMD2, a gene that allows
cells to become 6-AU tolerant [151], and indeed, IMD2 expression is in-
creased in ess1mutants [129]. Finally, using awell-deﬁned in vitro elon-
gation system, it was shown that extracts from ess1mutant cells are up
to 40% more efﬁcient at elongating a puriﬁed template than extracts
from the control wild-type cells (unpublished data). Adding back puri-
ﬁed Ess1 protein to a mutant extract reduced efﬁciency elongation.
The mechanism is currently unknown.
In summary, the use of conditional mutants has revealed a number
of transcriptional defects that occur when Ess1 activity is compromised.
The ﬁndings raise an important question: How does one protein play so
many different roles in transcription and RNA processing? The answer
seems to be that Ess1 targets the RNA polymerase enzyme itself and
by doing so is able to inﬂuence multiple steps in the process.
5. Mechanism(s) of Pol II regulation by Ess1
5.1. Overview
The major target of Ess1 in yeast is RNA pol II. To understand how
Ess1 targets RNA pol II and controls its functions, one must appreciate
the structure of the RNA pol II CTD and how it functions in RNA synthe-
sis and processing. In a nutshell, the CTD functions as molecular Velcro
to bind proteins required for nearly all aspects of RNA pol II function,
and the role of Ess1 is to modulate the stickiness of that Velcro. Like
the hook portion of Velcro, the CTD is ﬂexible and can attract a variety
of different binding proteins, and these proteins can have distinct
Fig. 5. Simpliﬁed version of the CTD code. One repeat of the heptad sequence found at the
carboxy-terminus of the Rpb1 subunit is shown. There are 26 repeats in yeast and 52 in
humans. The Ser2, Ser5 and Ser7 residues can be phosphorylated in any combination
(8 total), and the Ser2-Pro3 and Ser5-Pro6 bonds can exist in the cis or trans conformation
(4 different combinations). Thus, there are at least 8 × 4= 32 (×26 repeats) for a total of
832 potential conﬁgurations. Not shown are the potential phosphorylations at Tyr1, Thr4,
aswell as glycosylation at Thr4, and in humans, acetylation andmethylation at degenerate
Arg and Lys residues at position 7. See Egloff et al. [157] and other reviews cited in the text
for details.
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the “hooks” in the CTD thus favoring the binding of one protein over an-
other. In the absence of Ess1, there is a loss of coordination of protein ex-
change on the CTD that leads to defects in RNA production and in some
organisms, cell death or disease.
5.2. The CTD and the CTD code hypothesis
5.2.1. CTD basics
Eukaryotic RNA polymerase II is a large 12 subunit enzyme, the
largest of which is Rpb1, which in yeast is encoded by the RP021
(RPB1) gene. Rpb1 contains a C-terminal domain (CTD) unique to
eukaryotic pol II that consists of the repeats of the heptad sequence
(Y1S2P3T4S5P6S7)n. There are 26 nearly identical repeats of this se-
quence in the budding yeast CTD and 52 not quite so identical repeats
in the human CTD. As a general rule the more complex the organism
themore repeats, and themore that some repeats diverge from the con-
sensus. Before proceeding, it should be pointed out that the function of
the CTD is a fascinating topic and has been the subject of many studies.
Treatment of the CTD in the present review is limited to issues impor-
tant for understanding Ess1 function. For more detailed information
and collections of references please refer to the outstanding reviews
that are available [152–164].
Several important points need to be emphasized at this juncture.
First, the CTD is essential. Partial truncations are tolerated, but complete
deletions are inviable [165,166]. Second, not all of the repeats function
identically or have the same importance. Mutational analysis has dem-
onstrated that proximal (more N-terminal) vs. distal (more C-terminal)
show different genetic interactions and behave differently [165,167].
This is especially interesting to consider given that the beginning of
the CTD is located near the RNA exit channel on the polymerase holoen-
zyme, and helps recruit RNAprocessing enzymes. Third, the CTD is high-
ly ﬂexible. It is unstructured in solution, and can take on a variety of
conformations (how many is not known) depending on what protein
it is bound to. Fourth, the CTD repeat unit shown above is not the func-
tional unit although it is typically written this way for convenience. In-
stead the functional unit seems to be the better part of a di-heptad
repeat, and the spacing between repeats is critical [168]. Structure stud-
ies of a C. albicans capping enzyme shows that protein binding occurs in
a manner in which an individual repeat is looped out and the protein
makes contacts with non-adjacent repeats [169]. In all likelihood, the
functional repeat unit will depend upon which CTD-binding protein is
being considered. Fifth, the CTD is covalently and non-covalently modi-
ﬁed and these modiﬁcations help determine what proteins can bind
(elaborated below).
In the context of this review it is interesting to note the evolutionary
correlation between WW domain-containing PPIases and CTD-
containing polymerases. Organisms that have WW-domain containing
PPIases (Ess1/Pin1-type) have CTD-containing RNA polymerases. In
contrast, archaea, which do not have WW domain-PPIases, do not
have a CTD repeat. The reverse is not always true, however. Plants,
which do not have WW domain-PPIases do have a CTD-containing
Rpb1 subunit. So, while there are other ways to target PPIases to the
CTD [58,60], a WW-domain on an isomerase almost certainly means
that the enzyme will target a CTD-containing RNA pol II.
5.2.2. The CTD code: covalent and non-covalent modiﬁcation
The sequence and composition of the CTD are not likely to have oc-
curred by accident. Evolutionary pressure likely resulted in the selection
of residueswithmaximumversatility. This shortmotif can be covalently
modiﬁed by phosphorylation, primarily at serines 2, 5, and 7, but also at
Tyr1 and Thr4 [170]. In mammals, the Ser and Thr residues can also be
glycosylated [171,172], while degenerate Arg7 and Lys7 residues can
be methylated [173], or potentially acetylated, methylated, sumoylated
or ubiquitylated [157]. Moreover, the two Ser–Pro bonds can be non-
covalently modiﬁed by cis/trans isomerization [22,69].The potential for different combinations of modiﬁcations along a
sequence of CTD repeats is vast. For interesting discussions about evolu-
tion of the CTD and its potential information content, see the following
references [152,164,168,174,175]. Importantly, the Ser phosphoryla-
tions show characteristic patterns on the CTD as the RNA pol II complex
travels down the length of a gene [176–179]. This led to the idea that the
modiﬁcations constitute a “CTD code” that signals the recruitment and
eviction of protein co-factors to the polymerase to promote its transi-
tions (e.g. initiation→ elongation) and/or to help recruit the RNA pro-
cessing machinery [124,154,155,180]. Proline isomerization by Ess1
would be an integral part of this code (Fig. 5).
The patterns of CTD phosphorylation have been studied genome-
wide in yeast [181–183]. The general pattern observed for serine phos-
phorylations (S2, S5, S7) across protein coding genes is shown in Fig. 6A.
Ser5 and Ser7 phosphorylation peak early at the 5′ end of the gene near
the transcription start site, while Ser2 increases over the body of the
gene reaching peaking at the 3′ end near the transcription termination
site. The most recent of these studies conﬁrms this pattern is uniform
across nearly all protein-coding genes [184]. Similar patterns are ob-
served in mammalian cells [152]. Most of the kinases and phosphatases
that control the phosphorylation state of serineswithin the CTD in yeast
have been identiﬁed and have mammalian counterparts [180,185,186].
In higher organisms, there are additional CTD-kinases that respond to
cell cycle or extracellular signals. The pattern of phosphorylation along
the CTD does not seem to be critical for RNA pol II activity per se, and in-
deed the CTD is dispensable for transcription in vitro [187–190]. Instead
the CTD and its modiﬁcations are important for recruitment of protein
co-factors needed for RNA processing steps such as 5′-capping, splicing,
3′ cleavage, polyadenylation and mRNA packaging for nuclear export
(reviewed in) [154,155,158]. CTD phosphorylation is also likely to be
important for RNA pol II to elongate efﬁciently through chromatin and
for it to recruit histone-modifying enzymes [163].
5.3. Ess1 isomerizes the CTD preferentially targeting pSer5–Pro6
Using two-dimensional NMR (NOESY) to measure chemical ex-
change of proline γ-carbon protons, it was shown that Ess1 isomerizes
a CTD peptide, AS(YSPTpSPS)YS, which contains serine phosphorylated
at position 5, at a rate of 17.7 turnovers/s [22]. This was about six-fold
faster than a comparable peptide, AS(YpSPTSPS)YS, phosphorylated at
position 2 (2.8 turnovers/s). Ess1 also appears to target the Ser5 phos-
phorylated form of RNA pol II in vivo, as co-immunoprecipitation
Fig. 6. Phosphorylation pattern of the CTD as RNA pol II travels down a gene. (A) Patterns
of Ser2, Ser5, and Ser7 phosphorylation are averaged across the length of protein-coding
genes in yeast. TSS, transcription start site; TTS, transcription termination site. The up-
dated pattern is derived from genome-wide ChIP-chip using newer, more speciﬁc mono-
clonal antibodies [152,184,191]. pSer5 peaks early and diminishes as RNA pol II proceeds
from 5′→ 3′. pSer7 starts high and stays high until after 3′ cleavage and termination.
pSer2 increases and reaches a maximum at the termination site. (B) Comparison of Ser
phosphorylation levels at the 3′ termini of genes in wild-type vs. ess1H164R mutant cells.
Note the increase in both pSer5 and pSer7 as polymerase nears the TTS in ess1mutants.
pSer2 levels are slightly diminished. These results indicate that in normal cells, Ess1
helps reduce phosphorylation levels of Ser5 and Ser7, probably bymaking the CTD a better
substrate for the cis-speciﬁc Ssu72 phosphatase (see text for details).
Figure B is adapted from Bataille et al. [184], and is reprinted with permission from
Elsevier © 2012.
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modiﬁed enzyme [128]. An important caveat is that themonoclonal an-
tibodies used to detect the pSer5-speciﬁc form of RNA pol II (H14), also
recognize the pSer2/pSer5 doubly-phosphorylated forms [191]. Indeed,
genome-wide ChIP-chip data using additional antibodies suggest that
Ess1 preferentially associates with the doubly-phosphorylated form of
RNA pol II CTD (unpublished).
The preference of Ess1 for targeting pSer5–Pro6 was anticipated by
genetic experiments in which CTD serines 2 and 5 were mutated to
glutamic acid or alanine [165] and tested for growth in ess1 mutant
backgrounds [95]. Both S2E and S5E “partial”mutations (some repeats
are wild-type) in the CTD were synthetic lethal with the ess1H164R mu-
tant, indicating that they function in the same or converging pathways.
More informative however, was the ﬁnding that an S5A mutation sup-
pressed ess1H164R mutant, allowing it to grow at elevated temperature,
whereas a comparable S2A mutation did not. The interpretation is that
Ess1's in vivo function is to promote dephosphorylation of Ser5, and if
that residue is converted to alanine (de-phosphomimic), Ess1 function
becomes redundant. Consistent with this idea, when Ser5 is converted
to glutamic acid (phospho-mimic), Ess1 is unable to promote dephos-
phorylation, hence the synthetic lethality. Ess1 probably works in the
same pathway as Ser2 but at a distinct step, consistent with the failureof S2A to suppress (and S2E mutations being synthetic lethal). See
Wilcox et al. for additional details [95]. Finally, it is worth noting that
the S5A substitutions only suppressed ess1H164Rwhen located proximal-
ly in the CTD (more N-terminal), not when they were distal (more C-
terminal), suggesting that Ess1 has the most impact on the CTD
positioned near the RNA exit channel of the RNA polymerase. Taken to-
gether, the biochemical and genetic data support the idea that Ess1 is re-
cruited by both the pSer5 and pSer2/pSer5 doubly-phosphorylated CTD,
and it shows a preference for isomerizing the pSer5–Pro6 bond over the
pSer2–Pro3 bond.
5.4. Ess1 controls binding and activity of proteins required for transcription
and co-transcriptional RNA processing
5.4.1. Ess1 regulates the competition for CTD-binding
Ess1-catalyzed cis/trans isomerization of the CTD is likely to be crit-
ical for regulation of co-factor binding to RNApol II during the transcrip-
tion cycle. The best example for the role of Ess1 is in snoRNA
termination. While it is not yet possible to monitor the isomer state of
the CTD in vivo, chromatin IP can be used to measure the recruitment
of proteins along individual genes in wild-type vs. ess1 mutant cells.
Using this approach it was shown that Ess1 coordinates the recruitment
of Nrd1 and Pcf11 to the 3′-end of snoRNAs [129]. Nrd1, along with
Nab3 and Sen1 functions in 3′-end cleavage by recruiting the nuclear
exosome to process the transcripts of short non-coding RNAs
[139,140,192–195]. Pcf11, which is important for mRNA cleavage and
termination is also required for snoRNA termination [196–199]. In
ess1mutant cells, Nrd1 levels were increased at the 3′ ends of snoRNA
genes, while Pcf11 levels were decreased. Both proteins bind to the
nascent RNA, as well as to the phosphorylated CTD, Nrd1 preferring
the Ser5-phosphorylated form and Pcf11 preferring the Ser2-
phosphorylated form [197–199]. ChIP data suggest that Ess1 can referee
the competition between CTD-binding proteins [129]. For example, in
normal cells Ess1 promotes Nrd1 eviction from snoRNA 3′ ends to
allow Pcf11 binding and termination. In ess1 mutants, Nrd1 stays
bound blocking Pcf11 binding. Consistent with this competition
model, overexpression of Pcf11 rescues the growth defect of ess1 mu-
tant cells and reduces Nrd1 binding to snoRNA loci [129].
There is other evidence that Ess1 controls co-factor recruitment to
the RNA pol II complex. Compared to wild-type cells, ess1 mutants
show aberrantly high recruitment of TBP, TFIIB and Ceg1 (capping en-
zyme) to the initiation regions of cryptic transcripts [128]. This helps ex-
plain why CUT expression is increased in the ess1 mutants. These
examples suggest that faulty recruitment of RNA pol II co-factors and
a “mis-coordination” of a normally ordered process could explain
many, if not all of the transcriptional defects observed in ess1 mutant
cells (and Pin1 knockout cells).
Howmight Ess1 control recruitment of proteins to the CTD? Several
distinct mechanisms are possible. First, an indirect mechanism would
be to control the phosphorylation state of the CTD, thereby controlling
protein binding (Section 5.4.2). A second mechanism, would be to di-
rectly control binding by stimulating isomerization of the CTD so that
a preferred isomer is mademore available (Section 5.4.3). Other poten-
tial mechanismswould be for Ess1 to control accessibility via chromatin
structuremodiﬁcation, or to control the activity or intracellular localiza-
tion of the co-factors themselves (Sections 6.1, 6.2).
5.4.2. Ess1 controls phosphorylation state of the CTD
Evidence in yeast indicates that Ess1 helps lower CTD phosphoryla-
tion levels by assisting CTD-speciﬁc phosphatases. Overexpression of ei-
ther CTD phosphatase, Fcp1 or Ssu72 suppresses the growth defect of
ess1mutants [23,122,123], while overexpression of at least one CTD ki-
nase (Ctk1) exacerbates the growth defect [95]. These genetic experi-
ments predicted that CTD phosphorylation in ess1 mutants will be
abnormally high. Indeed, levels of CTD phosphorylation on Ser5 and
Ser7 levels are increased signiﬁcantly in extracts from ess1 mutant
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Ess1 but not a catalytically-deﬁcient mutant (C120R) reduces phosphor-
ylation of Ser5 below wild-type levels [129]. pSer2 levels are largely un-
affected. That loss of Ess1 activity causes CTD hyperphosphorylation was
conﬁrmed using ChIP tomonitor Ser2, Ser5 and Ser7 levels on individual
genes or genome-wide in ess1mutants [128,184]. Interestingly, in the
genome-wide study [184], the most pronounced increase in pSer5 (and
Ser7) levels occurred at the 3′ ends of protein-coding genes (Fig. 6B),
consistent with the observed defects in termination/3′-end formation
noted previously. Changes in the CTD phosphorylation pattern would
help explain, for example why Nrd1, which favors binding to pSer5-
CTD, increased abnormally at the 3′ end of genes in ess1mutants.
Ssu72 is a Ser5/Ser7-speciﬁc phosphatase [136,184,200,201] so it is
easy to understand why its overexpression rescues ess1 mutants,
where Ser5 and Ser7 are elevated. Less clear is why overexpression of
Fcp1,which is thought to be Ser2-speciﬁc,would suppress ess1mutants,
since pSer2 levels are not signiﬁcantly affected. One explanation is that
at high concentration, its substrate-speciﬁcity might be compromised
so that it dephosphorylates Ser5 and Ser7. Alternatively, it might be
that Ser2 dephosphorylation by Fcp1 stimulates Ssu72 to dephosphory-
late neighboring Ser5 residues (and vice versa). Crosstalk between these
two phosphatases has been shown to occur [184].
In summary, Ess1 promotes dephosphorylation of the CTD at Ser5
and Ser7, and this activity is likely to be an essential part of controlling
the so-called CTD code. Human Pin1 also seems to regulate CTD phos-
phorylation levels, but the one study in which this was examined, the
direction was opposite; Pin1 seemed to increase CTD phosphorylation
(on Ser5) [125]. Below, a mechanism by which Ess1 controls CTD phos-
phatase activity is considered.5.4.3. CTD-binding proteins show cis/trans stereoselectivity
A major prediction of the CTD code is that prolyl isomerization will
affect the binding of proteins to theCTD.While ChIP experiments clearly
show that Ess1 affects the binding of proteins to individual genes in vivo,
the results cannot directly demonstrate that binding is affected by iso-
mer status per se. However, over the last decade or so, nearly a dozen
structures of CTD-binding proteins bound to CTD peptides have been
solved (Table 2), and a number of themes have emerged. First, CTD-
binding proteins use a variety of distinct structural motifs to bind the
CTD. Second, the CTD takes on a different conformation depending on
the protein to which it is bound. And third, CTD-binding proteins do,
in fact, display a distinct preference for cis or trans isomers of the CTD
(as well as different phosphorylation states). Biochemical evidence
has also indicated that the activity as well as the binding of some pro-
teins may be affected by the cis or trans state of the substrate peptide.
A number of excellent reviews are available that summarize the results
of the structural studies [202–204]. Below I will highlight a few keyTable 2
Summary of structural studies for CTD-binding proteins.
Protein (binding motif) Phosphor. CT
Pin1 (WW) (human PPIase) Ser2-P, Ser5-P Yp
Cgt1 (C. albicans capping enzyme) Ser5-P 4
Pcf11 (CID) (yeast termination factor) Ser2-P PT
Scp1 (BRCT) (human phosphatase) Ser5-P PS
SCAF8 (CID) (human splicing factor) Ser2-P or Ser5-P V
MCE (human capping enzyme guanyltransferase subunit) Ser5-P [(
Rtt103 (CID) (yeast exo termination factor) Ser2-P 4
Ssu72 (Drosophila CTD phosphatase) Ser5-P PT
Ssu72 (human CTD phosphatase) Ser5-P SY
Nrd1 (CID) (yeast termination factor) Ser5-P 2
Set2 (H3K36 methyltransferase) Ser2-P, Ser5-P SP
CID = CTD interacting domain; WW= WW-domain; BRCT = BRCA1 C-terminal domain.ﬁndings for Ssu72, Nrd1 and Pcf11, three proteins whose function has
already been linked to Ess1.
Structures of the Ssu72 orthologs from human and Drosophila have
been solved [205,206]. Both were co-crystallized with CTD peptides
phosphorylated on Ser5, although the sequenceswere in a different reg-
ister relative to the consensus heptad repeat (Table 2). These structures
were the ﬁrst to show the CTD peptide bound to a protein in the cis-
isomeric state. This cis conﬁguration of the pSer5 CTD peptide with
Ssu72 contrasts with that found in the co-crystal of the Scp1 phospha-
tase, which binds a trans-isomer of a pSer5 CTD peptide [207]. The
human Ssu72 structure was solved using a full-length protein (a C12S
catalytic mutant) in a ternary complex with a scaffolding protein
Symplekin and a decamer CTD peptide. The functional equivalent of
Symplekin in yeast, the Pta1 3′-processing factor, interacts genetically
with Ess1 [122]. In the ternary structure, the CTDpeptidemakes a nearly
180° turn at the cis-proline and ﬁts within a narrow groove of the Ssu72
active site. Only a cis peptide can be accommodated in this highly-
constrained environment. Interactions are seen with CTD residues
Thr4, pSer5, Pro6 and Tyr1 of the next repeat. Another structure of the
ternary complex between Symplekin, Ssu72 and a CTD peptide was
solved, but in this case the peptide was phosphorylated on Ser7 and
bound in the opposite orientation as the pSer5 peptide, with all proline
bonds in the trans conformation [208].
In the Drosophila Ssu72 structure (a C13D/D144N catalytic mutant), a
number of interactions can be seen between residues in the Ssu72 active
site and the substrate that help explain the isomer-speciﬁcity [205]. In ad-
dition, the cis-conﬁguration of the heptamer peptide seems to be stabi-
lized by an intramolecular hydrogen bond between hydroxyl group of
the Thr4 residue (located at the−1 position relative pSer5–Pro6) and
the proline backbone carbonyl. This stabilizing interaction by Thr4 may
explain Ssu72's preference for pSer5 over pSer2. In the CTD, pSer2 is pre-
ceded by Tyr2, which would be unable to make this hydrogen bond, and
lead to steric clashes destabilizing the cis-conformation. While the intra-
molecular bond is likely to be important, it is probably not required, be-
cause while phosphorylation of Thr4 prevents bond formation and
lowers Ssu72 activity by about 4-fold, the co-crystal structure indicates
the overall conﬁguration of a CTD peptide within the active site remains
nearly identical [209].
Most relevant to Ess1 were the biochemical ﬁndings of Werner-
Allen et al. [205], which showed that Ess1 stimulated the phosphatase
activity of Ssu72 on CTD substrates, consistent with prior genetic and
molecular studies [129,184]. They found that only about 12% of the
phosphorylated CTD peptide in solution was present in the cis confor-
mation. This low percentage of cis-isomers was rate-limiting for Ssu72
phosphatase activity, and isomerization by Ess1 provided a kinetic ad-
vantage. Not only did Ess1 stimulate the phosphatase activity of Ssu72
on a small CTD peptide, it also did so on a “full-length” GST-CTD fusion
protein (26 repeats) and as expected, the stimulationwas saturable andD peptide Conformation Structure Refs.
SPTpSPS trans Extended coil [69]
repeat trans β-Like, looped [169]
SPSYpSPTSPS trans β-Spiral [210,211]
YSPTpSPS trans Extended coil [207]
arious trans β-Turn [230]
pSPSYSP)T]3 trans Extended β-like [204]
repeat (binds w/Pcf11) trans β-Turn [212]
pSPSYS cis β-Turn [205]
SPTpSPSYS cis β-Turn [206]
repeat cis β-Turn [213]
SYpSPTpSPSYpSPTpSPS ? n.d. [231,232]
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did not have any effect [205]. These ﬁndings are critical in that they pro-
vide a mechanism by which Ess1 can control the phosphorylation state
of the CTD and thus participate in writing the CTD-code. While it is not
known what percentage of CTD proline bonds are in the cis or trans
conﬁguration in vivo, these studies show that cis–trans interconversion
by Ess1 would provide a kinetic advantage to isomer-speciﬁc enzymes
like Ssu72.
Previous work showed that Ess1 controls the competition for bind-
ing to the CTD by the Pcf11 and Nrd1 3′-processing factors [129]. The
mechanismwas suggested to be indirect, through changes in CTD phos-
phorylation, as Pcf11 and Nrd1 have preferences for pSer2 and pSer5,
respectively.While thismay be part of themechanism, it is also possible
that Ess1 acts more directly because Pcf11 and Nrd1 also show strong
and distinct isomer-speciﬁc preferences.
The solution and crystal structures of the CTD-interacting domain
(CID) of Pcf11bound toCTDpeptides phosphorylatedon Ser2weredeter-
mined [210,211]. CID domains are found in many proteins and are char-
acterized by a right-handed bundle of eight α-helices that creates a
groove for CTD binding. The solution study shows that CTD peptides
phosphorylated at Ser2 exist in a disordered state, with the proline
bonds in both the cis (b30%) and trans (47/;70%) conformations [211].
Spontaneous intraconversion was measured from the millisecond to sec-
ond time scale or slower. The Pcf11CID selected the all trans formof a CTD
peptide using an induced-ﬁt binding mechanism to impart a β-spiral
structure on the CTD. Indeed, in the crystal structure, the central Ser2 is
phosphorylated within the CTD peptide and both pSer2–Pro3 and
pSer5–Pro6 bonds are in trans. In this structure cis bondswould not be ac-
commodated. Interestingly, Pcf11 binds the CTD cooperatively alongwith
another CID-containing 3′-end processing protein, Rtt103,which also rec-
ognizes a pSer-CTD peptide with all trans prolyl bonds [212].
Nrd1 stands in sharp contrast with respect to its isomer preference.
The solution structure of the CTD-interacting domain (CID) of Nrd1
bound to a two-repeat CTD peptide phosphorylated on Ser5 was solved
by NMR [213]. The 14-residue CTD motif adopts a β-turn conﬁguration
in which both pSer5–Pro6 bonds are in the cis conformation. The cis-
conformation of the peptidyl-prolyl bonds is required to maximize the
speciﬁc contacts required for CTD recognition. This is the only known
CID that prefers the cis conformation. Given this speciﬁcity, it is possible
that Ess1 plays a direct role in Nrd1 binding (i.e. independent of pSer
status) that has not previously been appreciated.
In summary, proline isomerization of the CTD by Ess1 is likely to play
an integral role in regulating the binding and/or activity of transcrip-
tional co-factors. For both Ssu72 and Nrd1, the low abundance of cis-
conformers would be made more kinetically accessible by increased
rates of isomerization by Ess1. For Pcf11, which binds cooperatively
with Rtt109, and requires a substrate with multiple repeats with se-
quential trans–trans conﬁgurations, Ess1 could also assist in a kinetic
manner. It is worth noting that the spontaneous interconversion rates
measured in peptides in vitro are probably much higher than what oc-
curs in vivo in intact proteins, even the relatively unstructured CTD.
Thus, Ess1 isomerization of the CTD would keep it in a constant state
of ﬂux, enabling the rapid exchange of proteins at a rate sufﬁcient for
transcription and RNA processing. In the case of coupled reactions (e.g.
isomerization/dephosphorylation), Ess1 would inﬂuence the equilibri-
um state of the CTD.
5.5. Ess1 is the trafﬁc cop of the RNA pol II transcription cycle
The genetic, biochemical and structural data suggest that Ess1 func-
tions at multiple steps of the transcription cycle in a “Trafﬁc Cop” type
mechanism (Fig. 7). That is, by changing the cis/trans state of pSer2–
Pro3 and pSer5–Pro6, Ess1 coordinates the ﬂow of trafﬁc of proteins
binding to and being released from the CTD, relieving congestion and
helping tomake each stepmore efﬁcient. There is probably not an abso-
lute requirement for Ess1 at any given step, as proteins wouldeventually bind and release, perhaps in response to spontaneous cis/
trans interconversion. For example, termination of snoRNAs and
mRNAs still occurs correctly ~80% ormore of the time, and transcription
in vitro occurs without Ess1/Pin1 [118,128,129,135]. However, without
Ess1, the inefﬁciencies in the transcription cycle, the aberrant RNAs pro-
duced, and cryptic transcription that occurs, probably combine to lead
to cell death, at least in yeast. In organisms where Ess1/Pin1 is not es-
sential, the defects may be better tolerated or there may exist compen-
satory mechanisms. However, these inefﬁciencies may insidiously
contribute to the developmental and disease phenotypes observed in
Pin1 under- or overexpressing tissues. A simple example was shown
in embryos with reduced Ess1 (dodo) in a pol II-sensitized background
(Fig. 4B). Also, as noted above, the requirement for Ess1/Pin1 is probably
higher during times of stress, when the efﬁciency of the transcription
cycle is probably more critical, especially at stress-responsive loci.
The fact that Ess1's role in transcription is conserved from yeast to
humans is also indicative of its importance. And, in some plants that
lack Ess1, its role seems to have been subsumed by other prolyl isomer-
ases (e.g. cyclophilins) [214]. Finally, with regard to the mechanism of
action, Ess1 on its own cannot change the equilibrium between cis
and trans isomers, but instead it provides a kinetic effect that accelerates
the availability of the “correct” isomer for a given CTD-binding protein.
In combination with a protein(s) that binds one isoform over the other
(i.e. a coupled reaction) Ess1 can change the local equilibrium (the CTD-
bound protein removes one isomer from the equation). This effect may
be necessary to boost the abundance of the cis isomer, which is probably
severely underrepresented in the CTD.6. Other transcription-related roles for Ess1
6.1. An Ess1-chromatin connection
Ess1 may play a role in organizing chromatin structure by control-
ling recruitment of histone-modifying enzymes. This would not be en-
tirely surprising given that the pol II CTD is important for recruitment
of histone modiﬁers [163,215–217]. Genetic interactions between ESS1
and genes encoding histone acetylase–deacetylase components, GCN5,
RPD3, and SAP30 infer that Ess1 inhibits histone deacetylase (HDAC) ac-
tivity [23,218]. Combined with biochemical and pharmacologic experi-
ments, the overall effect of Ess1 is likely to be an increase in histone
acetylation, thus leading to gene activation [218]. The mechanism by
which Ess1 may control histone acetylation state is not known.
ESS1 also shows genetic interactions with SET1, SET2 and JHD2, en-
zymes responsible for the methylation state of histone H3 lysine 4
(H3K4) and H3 lysine 36 (H3K36). For example, set1Δ is synthetically
lethal with ess1H164R and jhd2Δ suppresses ess1H164R [128]. As the genet-
ics predicts, levels of H3K4 trimethylation are sharply reduced in ess1
mutant cells. These results suggest that Ess1 might recruit Set1 (H3K4
methylase), which is known to prefer the pSer5 CTD and is associated
with active transcription, or that Ess1 inhibits recruitment of Jhd2
(H3K4 demethylase). The reduction in H3K4 trimethylation levels in
ess1mutants might explain why cryptic transcripts in these cells are el-
evated. Loss of Ess1 would result in reduced H3K4me3 at cryptic pro-
moters, which can result in a failure to recruit the histone deacetylase
complex (Rpd3L) leading to derepression [219].
Despite the strong genetic suppression of ess1H164R mutants by set2Δ,
the levels of H3K36 trimethylation, predicted to increase, did not change
detectably in ess1mutants. Changes inH3K36 trimethylation are typically
more difﬁcult to detect as the modiﬁcation is relatively stable (B. Strahl,
U.N.C., pers. comm.). Set2 contains a WW-domain and binds the
doubly-phosphorylated CTD (pSer2/pSer5) and is associated with elon-
gating polymerase [220,221]. In summary, there is a strong link between
Ess1 and chromatin modiﬁcation, but the mechanisms by which Ess1 af-
fects the enzymes involved in histone acetylation and methylation are
unknown.
Fig. 7. Ess1 is the trafﬁc cop of the transcription cycle. Diagram shows the transcription cycle from preinitiation complex formation, to initiation, elongation, RNA splicing, 3′-end process-
ing, termination and re-initiation. During these steps, the CTD of Rpb1 undergoes a complex regime of dynamic covalent (phosphorylation) and non-covalent (isomerization) modiﬁca-
tions. These changes in the CTD effect the recruitment and eviction of transcriptional co-factors that are required for of RNA synthesis and maturation. Only a single CTD heptad repeat
(Y1S2P3T4S5P6S7) plus a few ﬂanking residues is shown. In this model, Ess1 plays the role of a trafﬁc cop: it helps direct the heavy trafﬁc of protein co-factors so that they can bind and
be released from the CTD in a coordinated and efﬁcient manner. Ess1 isomerization is probably not required for transcription and RNA processing per se, but increases its efﬁciency,
just as you can take a trafﬁc cop away from a busy intersection, cars would still get through, just not as efﬁciently and with a lot more crashes. Arrows from Ess1 show steps that Ess1
promotes, and blocked arrows show steps that Ess1 attenuates.
The backbone of this ﬁgure was adapted from Zhang [162] © Creative Commons 2012.
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In a large-scale synthetic genetic array screen, Ess1 was linked to a
number of transcription regulators including the cell cycle transcription
factors Swi6 and Whi5 [89]. Surprisingly, the expression of the genes
encoding these proteins was not affected. Instead their nuclear-
cytoplasmic shuttling was defective in ess1 mutant cells. Using GFP-
tagged proteins and in vitro binding assays, it was shown that Ess1 is
required for nuclear localization of Swi6 and Whi5, and that Ess1 binds
peptides corresponding to the nuclear localization sequence (NLS) of
Swi6, and the NLS and nuclear export sequences (NES) of Whi5 [89].
The NLS and NES sequences each contain between one and three Ser-
Pro motifs, and Ess1 binding as assayed using biolayer interferometry,
was dependent upon phosphorylation of these serines. These results sug-
gest amodel inwhich Ess1 regulates localization of Swi6 andWhi5 either
indirectly by stimulating their dephosphorylation (a prerequisite for nu-
clear entry), or directly by causing conformational changes that effect in-
teractions with nuclear pore complexes (both importins and exportins).
The exact mechanism remains to be determined. The Cdc14 phosphatase
is known to dephosphorylate the NLS and NES sites in Swi6 and Whi5
[222,223], but it is not known whether it is isomer-speciﬁc. Swi6 and
Whi5 are the only targets of Ess1 other than the CTD identiﬁed so far in
yeast. Control of nuclear localization of transcription regulators has
been previously shown for Pin1 inmammalian cells [16,224], but the de-
tailed mechanisms have not been worked out.7. More questions than answers
While much is known about Ess1 and its role in transcription, more
remains to be learned. The tools of genetics, genomics, and the bio-
chemistry of binding and isomerization have been informative. We
know of many steps in transcription that require Ess1 for efﬁciency
and have a good idea of how Ess1 might affect the enzymes required
for co-transcriptional RNA processing. However, more remains to be
discovered. For example, RNA splicing, which is relatively rare in
yeast, is likely to depend upon Ess1 for efﬁciency (more so for Pin1 in
humans) as it is a co-transcriptional process and is inﬂuenced by elon-
gation rates [154,155,158,225]. mRNA export is also likely to be depen-
dent upon Ess1. Genes encoding a number ofmRNAexport factors show
interactions with ESS1 (unpublished data). Essentially all CTD-related
activities in the cell, including those not directly related to RNA biogen-
esis, such as transcription-coupled repair, recombination, and gene si-
lencing will likely be inﬂuenced by Ess1. There are already examples
linking the CTD and Pin1 to DNA repair [226–229]. And, if Swi6 and
Whi5 serve as examples, then it is likely that other Ess1 targets will be
discovered in yeast.
Perhaps more pressing, however, is to determine the exact mecha-
nisms bywhich Ess1 functions in transcription, such as during elongation
and mRNA 3′-end formation. Studies thus far reveal a gap between the
existing in vivowork, mostly genetic/genomic and in vitroworkwith pu-
riﬁed isomerases and peptides. A major impediment is that it is not
329S.D. Hanes / Biochimica et Biophysica Acta 1839 (2014) 316–333currently possible to monitor the isomerization state of the CTD or any
other protein in vivo. New tools need to be developed, such as isomer-
speciﬁc monoclonal antibodies, or FRET-based or other dynamic in vivo
assays to detect changes in the isomerization state of substrate proteins.
In addition, better in vitro systems are likely to be required to detect ef-
fects of Ess1, which may be subtle and require that multiple factors
(whose binding Ess1 inﬂuences in vivo) are present in the appropriate
rate-limiting amounts. Having a large excess of a particular enzyme, for
example a CTD phosphatase, will likely obscure the effect of isomer-
speciﬁcity on substrate preferences. Moreover, in the case of competing
proteins, excessive amounts of one protein (or an absence of it) may ob-
scure the effects of Ess1 on binding by another protein. These are difﬁcult
challenges that will require the efforts of many.
In the short term, determining the structures of additional CTD-
binding proteins with peptide substrates will add important informa-
tion to the repertoire of cis- or trans-speciﬁc enzymes. Genome-wide
approaches, such as ChIP-chip and ChIP-seqwill reveal the global effects
of Ess1 on recruitment of transcriptional co-factors and chromatinmod-
iﬁers. Also, detailed examination of individual genes by genetic ap-
proaches combined with ChIP and perhaps ChIP/reChIP-type methods
and detailed RNA analysis will help elucidate the effects of Ess1 on indi-
vidual steps in transcription.
Finally, one of the most interesting challenges is to ﬁgure out how
Ess1, and indeed all CTD-binding proteins, operate on the long and re-
peated heptapeptide motifs in the CTD. Even in yeast, with only 26 re-
peats, there are 52 potential sites for Ess1 binding and isomerization.
Does Ess1 target all these sites, and which sites get isomerized and
when?Which if any processes, such as isomerization and phosphoryla-
tion/dephosphorylation are processive and what is the mechanism of
processivity? And does Ess1 isomerization help direct different proteins
to different regions along the lengthof theCTD? In short, we haveﬁnally
begun to recognize the importance of Ess1-dependent isomerization of
the CTD for transcription, but understand very little of how it works. It is
essentially an unﬁnished book, waiting to be completed by creative and
dedicated investigators.
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